Abstract: An automated docking procedure was applied to study the binding of a series of μ-and δ-selective ligands to ligand-specific μ-and δ-opioid receptor models. Short-time molecular dynamic simulations were used to obtain ligand-specific μ-and δ-opioid receptors from arbitrarily chosen models of the active form of these receptors. The quality of receptor model depended on the molecular volume of the ligand in the receptor-ligand complex used in the molecular dynamic simulations. Within a series of ligands of similar size (volume), the results of ligand docking to the obtained ligand-specific receptor conformation were in agreement with point mutation studies. The correlation of the calculated and the experimentally determined binding energies was improved in relation to the initial receptor conformation.
INTRODUCTION
Three types of opioid receptors: μ, δ and κ (or MOR, DOR and KOR, respectively), are involved in pain regulation by inhibiting neuronal adenylyl cyclase activity, but they also participate in the regulation of multiple other effectors. 1 There are also studies indicating that the δ-opioid receptor and/or its specific ligands are involved in cardioprotection. 2 Based on the results of pharmacological investigations, 3 opioid receptors have been subdivided into receptor subtypes, but the molecular basis of these subtypes remains to be resolved. Both, MOR and DOR have been cloned. [4] [5] [6] A hypothesis was made 7 that selective ligands might bind the same receptor but at different binding sites. The ability of the selective ligands to bind their respective binding site would depend on the conformational state of the opioid receptor. 7, 8 The regions of MOR and DOR involved in ligand binding and mediation of receptor function have been identified: a) by the construction of chimeric receptors containing sequences of MOR or DOR receptors, 9-14 b) by site-directed mutagenesis of specific amino acid residues [15] [16] [17] [18] [19] [20] [21] and c) by the construction of truncated mutant receptors. [22] [23] [24] [25] [26] In the case of DOR, it was found by point-mutation experiments 21 that Asp95Asn mutation reduced the affinity of many DOR-selective peptidic and non-peptidic agonists for DOR. Studies 5 on chimeric and site-mutagenized DOR established the importance of the third extracellular loop (EC3) arginine amino acids for the binding of peptidic ligands while non-peptidic ligands were unaffected. Site-directed mutagenesis experiments showed 16 that Asp128 contributes to the stabilization of the binding pocket. Mutations of amino acids Tyr129Phe, Trp274Ala and Tyr308Phe suggested that these aromatic residues might be a part of an opioid binding domain. Chimeric receptors and the alanine scan method were used 11 to show that Leu295, Val296, Val297 and Ala298 of the EC3 loop are important for the binding of DOR-selective ligands. The amino acids Trp284 (TM6) and Ser312 (TM7) are important but to a lesser degree. It was also found 12 that modifications of the second extracellular loop (EC2) had no effect on ligand binding. Other chimeric receptor studies 13 demonstrated that the sixth transmembrane domain (TM6) and the third extracellular loop (EC3) are absolutely critical for δ-opioid receptor selectivity. Point mutations emphasized the importance of Leu300, Ala298, Ala299 amino acids, and the unimportance of Arg291 for ligand binding. Val281 had moderate effect on ligand binding. 13 It was suggested 18 that interactions [Asp128(TM3)-Tyr308 (TM7) and Tyr129 (TM3)-His278(TM6)] maintain the δ-receptor in an inactive conformation. Point-mutation experiments 19 confirmed that Trp284 (TM6) is important for the binding of ligands to the DOR, and that amino acids at the extracellular end of TM6 and TM7 are key residues for δ-ligand selectivity. Binding studies 27 on a series of non-peptidic DOR ligands revealed that the binding site of these ligands is between TM5 and TM7 of the DOR. The binding pocket for most DOR-selective ligands is located close to the EC3 loop and between the transmembrane helices TM3, TM6 and TM7.
It was found by chimeric receptor studies 9 that the major determinant for the binding of MOR-selective alkaloids exists in the region spanning the transmembrane segments TM5 to TM7 of the MOR. Segments TM6 and TM7, as well as the third extra-cellular (E3) loop of the μ-receptor, were important 28 for the binding of agonists, such as morphine and fentanyl analogs, while the first extra-cellular loop (E1) was not important for MOR-selective non-peptide ligands. Site directed mutagenesis studies 15 indicated that Asp147 is the primary binding site in the MOR, as the counter ion for the protonated nitrogen of opioid ligands. The MODELING LIGAND SPECIFIC RECEPTOR CONFORMATION 1249 importance of charged residues in TM2 (Asp 114), TM3 (Asp147) and TM6 (His297) was evidenced, 15 as well as the modest involvement of N-and C-terminal domains in the ligand-receptor interactions. Site directed mutagenesis studies [29] [30] [31] established the importance of the TM7 residues Cys321, Tyr326, Trp318 and His319 and the TM3 residue Tyr148 for the activation of MOP. It was also established by mutation experiments, 32 that Asn230 of TM5 is involved in the binding of morphine.
Some experiments [33] [34] [35] [36] suggested that important conformational changes in the receptor accompany ligand binding. Receptor states were discovered that can be activated without the effects of an agonist, 37 shifting thus the understanding of receptor activation from a model of inactive and active conformations of a receptor 38 to theories of multiple signaling states whereby each agonist could import its own unique active conformation. 39 In this work, molecular dynamics were used to model ligand-specific receptor conformation from an arbitrary model of an active receptor. This ligandspecific receptor conformation is expected to provide more realistic geometry of a receptor-ligand complex obtained by ligand docking, and to give a better correlation between the calculated and experimentally determined binding energies within a series of closely related ligands. Molecular volume was the molecular descriptor which defined the closely related group of ligands.
COMPUTATIONAL METHODS
All computations were realized on an Intel(R) Core(TM)2 Quad CPU Q9650 at 3.00 GHz or Silicon Graphics® Octane2 workstation. The initial active forms of the MOR and DOR models were obtained from Prof. H. I. Mosberg. The receptor models were based on the structure of the β2-adrenergic receptor (PDB code 2rh1) and were modeled in a receptorligand complex with cyclic pentapeptide agonist ligands. 40 The series of agonists (Tables I, II and III) were at first docked to the obtained original models of the active forms of the MOR or DOR. The receptor models were initially treated as rigid. In the second docking experiment, the flexibility of the binding pocket amino acids was taken into account. The automated flexible ligand docking was performed by the Auto Docking program. 41 In the subsequent docking experiments, the receptor models were optimized as follows. The selected ligands were manually docked to the original (obtained) receptor models using Accelrys Discovery Studio ® (DS 2.5.5) visualizer. The orientation of the ligand inside the binding pocket was such as to: 1) provide interactions between the protonated nitrogen of the ligand and the important receptor residues (Asp 147 of TM3) in the MOR, or the corresponding Asp128 in the DOR; 2) form a hydrogen bond between the OH group of the ligand and the His297 residue of TM6 in the MOR (or His 278 in the DOR) and 3) provide close interactions with Trp318 of TM7 in the MOR (or Leu300 in the DOR). The resulting complex structure was refined by molecular mechanics with a conjugated gradient algorithm in vacuum 1252 SENĆANSKI et al. to a RMS gradient below 0.4 kJ mol -1 nm -1 , using CHARMm force field 42 with Momany--Rone charges. 43 A short molecular dynamics simulation (5 ps) with 0.1 fs time steps at 300 K was then applied. The lowest energy structure of the complex was selected and re-optimized providing a ligand-specific receptor conformation. Docking with Auto Dock Vina was repeated using the ligand-specific receptor conformation as a rigid target. Calculated values 44 were built by application of HyperChem program 45 and subsequently optimized by the semi-empirical PM3 method of the same program. The protein receptor and the ligands were prepared with MGL tools. 46 A 30×30×30 grid was applied, with the grid center positioned between Asp147 and His297 in the MOR (Asp128 and His278 in the DOR). The docking process was performed with exhaustiveness equal to 100. The resultant ligand orientations and conformations were scored based on binding energies (the cut-off value for the energies was 8.4 kJ mol -1 ), and by the formation of the salt bridge (shorter than 0.25 nm). The lowest binding energy conformations were further evaluated based on their distances to the important amino acids. The conformation with the lowest binding energy, with a salt bridge shorter than 0.25 nm and with maximum number of close contacts to the important amino acids is referred to as the preferred conformation.
RESULTS AND DISCUSSION
Automated docking of compounds 1-21 to the original MOR model, 40 and compounds 22-28 to the original DOR model 40 resulted in a similar docking pattern. The ligands 1-11 in the MOR, in the best orientation for possible salt bridge formation with Asp147, are presented in Fig. 1 . However, all the ligands are located in the wide cavity near the extracellular ends of the transmembrane helices TM3, TM6 and TM7. The distance between Asp147 (Asp128 in the DOR) and the protonated nitrogen of the ligand (O -⋅⋅⋅H-N + ) was at least 0.6 nm, Fig. 1 . Therefore, the key interaction for ligand binding and activation, which is be- lieved to be the salt bridge formation, was not predicted by the model. The same was true for MOR ligands 12-21 and DOR ligands 22-28. The area in the original receptors, around Asp147 (Asp128 in the DOR) was too narrow to accommodate even small ligands and to allow the formation of the salt bridge. The use of receptors with flexible amino acids within the binding pocket did not improve the model. Moreover, the correlation of the calculated binding energies to the experimentally determined ones was poor, the correlation coefficient being -0.36 for the compounds 1-11, Table IV . The experimentally determined and the calculated binding energies had opposite trends, Fig. 2 .
This was expected since the original active receptors used in this work were modeled with voluminous molecules, i.e., naphthylalanine-substituted cyclic pentapeptide 40 ligands. This is also in agreement with earlier results 47 which suggested that ligands bind to their ligand-specific receptor conformations. An effort was made to find the ligand specific receptor conformations of the MOR and DOR for ligands 1-28 by short molecular dynamics simulation of the complex obtained by manual docking of a specific ligand to the original receptor model. 40 Since Auto Dock Vina does not take into account receptor flexibility, a unique receptor had to be modeled for a set of ligands of similar size. Therefore the MOR ligands were divided into two groups (group 1-11, Table I , and group 12-21, Table II) based on their molecular volume, and the DOR ligands formed the third group, Table III. At least one representative molecule of small volume in each group was manually docked to the original receptor in such an orientation that a salt bridge was formed between the protonated nitrogen of the ligand and the Asp147 (Asp 128) of the receptor, and hydrogen bond formation was enabled between the phenolic hydroxyl group and the His297 (His278) of the receptor. The structure of a complex was optimized and subsequently submitted to the short molecular dynamics run. The lowest energy conformation of the complex found by molecular dynamics was isolated and re-optimized. The ligand was removed and the optimized receptor model was used for docking. The collected binding energies E b , and the resulting docking structures are presented in Table  V , and Fig. 3 , for the series 1-11. In this group of ligands, compounds 1-6 and 10 were used for receptor optimization and docking in order to investigate the effect of ligand size on the quality of the receptor model. It can be seen in Table  V and Fig. 2 that all ligands (1-4) with a small molecular volume improved the receptor model. This is illustrated by the increase of binding energy correlation coefficient from -0.36, for the initial MOR, to 0.83 for the receptor optimized with morphine (4) as the ligand. Only compound 1 insignificantly improved the correlation coefficient, just to a value of 0.22. The correlation coefficient for the larger molecules 5, 6 and 10 were either close to zero or had negative value. The best correlation of E b was achieved with compounds 3 and 4 which, besides low molecular volume, had maximum number of hydrogen bond donors and acceptors. In addition, in the morphine (4) optimized receptor, the preferred ligand conformation was always the lowest energy conformation for ligands 1-10, Fig.  3 . Only thebaine (11) had no conformation with a salt bridge; it was in fact too big to enter the binding site created by the receptor optimization, which might be 1256 SENĆANSKI et al.
the reason for its weak binding to the MOR, K i = 7400. Therefore, although the original binding site at the top of the receptor was still present and accommodated the ligands, complex optimization provided the receptor model with a new binding site where the ligands bind with higher affinity. Based on these data, it was concluded that morphine 3-esters, Table II , are too large to use in the morphine-specific receptor model; hence, they must have their own, ligand-specific receptor model derived from a complex optimized with a representative ligand for the series 12-21. Docking of compounds 12-21 to the original MOR resulted in complex structures with ligands positioned high in the receptor, between helices TM2-TM7, similar to compounds 1-11. None of the ligands had a salt bridge with Asp147. Ligand 15 was selected to be the representative ligand for receptor optimization because of its lowest molecular volume. The calculated and experimentally determined binding energies for compounds 12-21 are reported in Table VI . The correlation of E b (calcd) and E b (exp) was poor, the correlation coefficient being close to zero. However, lower binding energies were obtained and the qualitative picture was improved, Fig. 4 . The low energy conformations of the ligands have a salt bridge with Asp147 and close interactions with other important amino acids of the binding pocket, such as a hydrogen bond to Tyr148 and electrostatic interaction with His297. Only for compounds 14, 18 and 21, the experimentally determined K i values of which were high and thus indicated weak binding, were conformations with a salt bridge not among the low energy ligand conformations. The selected DOR agonists are presented in Table III and the resultant binding energies and molecular properties are reported in Table VII perimentally determined E b values and the calculated ones was low, close to zero, Fig. 5 . Ligand 26 with its low molecular volume was used for optimization of the receptor to its ligand specific conformation. The docking results with the optimized receptor are also reported in Table VII . The ligand preferred conformations whose binding energies are reported, are the ones with low binding energies (within 8.4 kJ mol -1 above the global minimum), with a salt bridge shorter than 0.25 nm and the maximum number of interactions with other important amino acids of the binding pocket, Fig. 6 . The trend of the binding energies for the DOR ligands 22-28 showed improvement. While the correlation coefficient was close to zero, as in the case of the original receptor, it was corrected to 0.57 (R 2 = 0.33) for the optimized receptor, which confirms the necessity of using ligand specific receptor conformations for docking. 
CONCLUSIONS
An automated docking procedure, combined with a short molecular dynamics simulation, was applied in order to determine ligand specific receptor conformations for MOR and DOR receptors. It was established that one receptor conformation cannot reproduce correctly the binding of different ligands. Instead, a method is proposed to model a ligand specific receptor conformation for a series of ligands of similar size. The method consists of using an arbitrary model of an active receptor, manually docking a ligand representative of a series of ligands of similar size to the receptor, following the existing knowledge of key ligandreceptor interactions; optimizing the receptor-ligand complex; allowing the receptor and the ligand to adjust their conformations in a short molecular dynamics run; extracting the most stable receptor-ligand complex structure and re-optimizing its geometry. The receptor models obtained in this way were used for docking of different MOR and DOR ligands. They improved the resulting receptor ligand complexes both qualitatively (increased number of close interactions with amino acids important for binding, as found by point mutation studies) and quantitatively (improved correlation between the experimentally measured and calculated binding energies).
